Finance

Lists
ANIP:NASDAQ
ANI Pharmaceuticals Inc Common Stock
$71.44
+0.53%
(+0.38) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANIP...
Open
$70.54
High
$72.00
Low
$70.37
Mkt. cap
1.62B
Avg. vol.
432.92K
Volume
383.86K
P/E ratio
14.32
52-wk high
$87.76
52-wk low
$67.14
EPS
$4.99
Beta
0.45
Shares outstanding
22.72M
No. of employees
970
Open
$70.54
High
$72.00
Low
$70.37
Mkt. cap
1.62B
Avg. vol.
432.92K
Volume
383.86K
P/E ratio
14.32
52-wk high
$87.76
52-wk low
$67.14
EPS
$4.99
Beta
0.45
Shares outstanding
22.72M
No. of employees
970
News stories
From web sources and news partners
About ANI Pharmaceuticals Inc Common Stock
CEO-
Employees970
Founded2001
HeadquartersBaudette, Minnesota, United States
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 7 analysts giving stock ratings to ANIP in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ANIP in the last 3 months.
Highest
Current $71.44
$121.00 (+69.37%)
Average
$105.14 (+47.17%)
Lowest
$85.00 (+18.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gary Nachman
Canaccord Genuity
Hold
Maintained
$90.00
+26%
11/06/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$121.00
+69.4%
11/06/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$121.00
+69.4%
11/05/2026
Ekaterina Knyazkova
J.P. Morgan
Buy
Maintained
$115.00
+61%
10/22/2026
Les Sulewski
Oppenheimer
Hold
Initiated
$85.00
+19%
09/23/2026
Unknown Analyst
Oppenheimer
Hold
Initiated
$85.00
+19%
09/23/2026
Daniel Clark
Leerink Partners
Buy
Initiated
$104.00
+45.6%
09/09/2026
Glen Santangelo
Barclays
Buy
Maintained
$100.00
+40%
08/25/2026
Unknown Analyst
Jefferies
Buy
Reiterated
$120.00
+68%
08/10/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
-
-
05/08/2026
David Amsellem
Piper Sandler
Buy
Maintained
$111.00
+55.4%
04/23/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$120.00
+68%
03/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
247.06M
237.46M
266.04M
290.78M
Cost of goods sold
100.27M
93.58M
100.16M
111.53M
Cost of revenue
100.27M
93.58M
100.16M
111.53M
Research and development expenses
12.26M
10.60M
14.75M
13.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
82.29M
73.66M
91.66M
94.86M
Operating expense
117.16M
105.17M
126.05M
127.41M
Total operating expenses
217.43M
198.76M
226.21M
238.94M
Operating income
29.63M
38.71M
39.84M
51.84M
Other non operating income
-
-
-
-
EBT including unusual items
31.48M
40.22M
37.10M
49.04M
EBT excluding unusual items
26.07M
34.29M
35.73M
48.54M
Income tax expense
3.99M
10.73M
12.39M
13.89M
Effective tax rate
12.67%
26.68%
33.39%
28.33%
Other operating expenses
-
-
-
-
Net income
27.49M
29.49M
24.71M
35.15M
Net profit margin
11.13%
12.42%
9.29%
12.09%
Earnings per share
2.33
2.05
2.21
2.70
Interest and investment income
3.16M
3.78M
3.86M
4.53M
Interest expense
-7.57M
-7.55M
-7.50M
-7.59M
Net interest expenses
-4.41M
-3.77M
-3.64M
-3.06M
Depreciation and amortization charges
22.61M
20.92M
19.64M
19.55M
EBITDA
52.24M
59.62M
59.48M
71.39M
Gain or loss from assets sale
87.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps